» Articles » PMID: 17949970

MEIS and PBX Homeobox Proteins in Ovarian Cancer

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2007 Oct 24
PMID 17949970
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Three amino-acid loop extension (TALE) homeobox proteins MEIS and PBX are cofactors for HOX-class homeobox proteins, which control growth and differentiation during embryogenesis and homeostasis. We showed that MEIS and PBX expression are related to cisplatin resistance in ovarian cancer cell lines. Therefore, MEIS1, MEIS2 and PBX expression were investigated immunohistochemically in a tissue microarray (N=232) of ovarian cancers and ovarian surface epithelium (N=15). Results were related to clinicopathologic characteristics and survival. All cancers expressed MEIS1, MEIS2 and PBX in nucleus and cytoplasm. MEIS1 and 2 only stained nuclear in surface epithelium. Nuclear MEIS2 was negatively related to stage, grade and overall survival in univariate analyses. Additionally, MEIS and PBX RNA expression in ovarian surface epithelium and other normal tissues and ovarian cancer versus other tumour types using public array data sets were studied. In ovarian cancer, MEIS1 is highly expressed compared to other cancer types. In conclusion, MEIS and PBX are extensively expressed in ovarian carcinomas and may play a role in ovarian carcinogenesis.

Citing Articles

Interaction Between Malat1 and miR-499-5p Regulates Meis1 Expression and Function with a Net Impact on Cell Proliferation.

Fahim S, Ragheb M, Fayed I, Osama A, Karam A, Magdeldin S Cells. 2025; 14(2).

PMID: 39851553 PMC: 11764005. DOI: 10.3390/cells14020125.


Cleft palate, congenital heart disease, and developmental delay involving heterozygous mutations found in the patient with attention deficit hyperactivity disorder: a case report.

Shen F, Li J, Li D, Zhou H Front Pediatr. 2025; 12():1500152.

PMID: 39776641 PMC: 11703840. DOI: 10.3389/fped.2024.1500152.


The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells.

Croft W, Pounds R, Jeevan D, Singh K, Balega J, Sundar S Commun Biol. 2024; 7(1):1211.

PMID: 39341888 PMC: 11438996. DOI: 10.1038/s42003-024-06909-9.


MEIS2 suppresses breast cancer development by downregulating IL10.

Xiao Y, Liu Y, Sun Y, Huang C, Zhong S Cancer Rep (Hoboken). 2024; 7(5):e2064.

PMID: 38711262 PMC: 11074520. DOI: 10.1002/cnr2.2064.


Low-grade undifferentiated sarcoma with MEIS1::NCOA2-rearrangement primary to the lung: a case report.

Coty-Fattal Z, Carter B, Volek M, Obeidin F Diagn Pathol. 2024; 19(1):65.

PMID: 38678288 PMC: 11055358. DOI: 10.1186/s13000-024-01484-3.